MedTrace Logo

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

NCT04914117 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-06-22

No results posted yet for this study

Summary

This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).

Conditions

  • Unresectable Solid Tumor
  • Metastatic Solid Tumor
  • Locally Advanced Solid Tumor

Interventions

DRUG

RC118 for injection

RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2022-11-15
Completion
2023-03-11

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914117 on ClinicalTrials.gov